Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)
- Sponsor
- Groupe Francais De Pneumo-Cancerologie
- Study ID
- NCT00418704
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 65 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Erlotinib — DRUGTarceva (150 mg) is a pill you take once a day -- every day
- taxotere — DRUGTaxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.
Study Details
The purpose of this study is to determine duration before progression of first-line treatment chemotherapy following erlotinib in second-line comparing erlotinib in first-line following chemotherapy in second-line in old patients with none small cell lung cancer.
Key Dates
- First listed
- Jan 5, 2007
- Start date
- May 31, 2006
- Status verified
- Sep 2013
- Primary completion
- Jun 30, 2006
- Completion
- Jun 30, 2009
Study Design
- Enrollment
- 100 participants (actual)
Related Studies
- The Effect of Beta-glucan in Non-Small Cell Lung CancerRecruiting · University of Louisville · Louisville, Kentucky
- Dabrafenib and/or Trametinib Rollover StudyPHASE4 · Recruiting · Novartis Pharmaceuticals · Scottsdale, Arizona
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Tumor Cell and DNA Detection in the Blood, Urine, and Bone MarrowRecruiting · University of Missouri-Columbia · Columbia, Missouri